Development of CNS dysfunction in the setting of hematopoietic stem cell transplant (HSCT) has been previously shown to predict for subsequent second organ dysfunction and death. In this paper, we describe the characteristics of this isolated CNS dysfunction, and its relationship to multiple organ dysfunction syndrome (MODS) after HSCT. Twenty-one of 186 patients undergoing HSCT developed CNS dysfunction as their first organ dysfunction a mean of 22.8 ± 0.9 days after the start of the preparative regimen. Compared with 137 patients who developed no organ dysfunction, patients presenting with CNS dysfunction were more likely to have undergone allogeneic HSCT (P = 0.001) and to have received a total body irradiation-based regimen (P = 0.001), and were less likely to have been transplanted for lymphoma (P = 0.008). Patients who developed CNS dysfunction were more likely to die than those with no organ dysfunction (P Ͻ 0.001). Of the 21 patients who developed CNS dysfunction, 48% resolved their dysfunction by a mean of 4.6 days later without progression to second organ dysfunction, and 90% of these patients survived to day 100. Fifty-two percent of patients with CNS dysfunction progressed to second organ dysfunction (pulmonary or hepatic) a mean of 5.5 days later, and only 36% survived to day 100 (P = 0.02). The patients who progressed to second organ dysfunction and those who did not were not different in terms of type of HSCT (allogeneic vs autologous), stem cell source (blood vs bone marrow), age, diagnosis or preparative regimen. Development of CNS dysfunction in the setting of HSCT, as with other organ dysfunctions (such as hepatic veno-occlusive disease), probably represents an early manifestation of a systemic disorder predisposing for MODS, increasing the risk of transplant-related mortality. Early systemic therapies directed at modulating this systemic disorder are probably indicated. Bone Marrow Transplantation (2000) 25, 79-83.
Organ system dysfunction is a frequent complication of hematopoietic stem cell transplantation. Single and multiorgan dysfunction may be due to the culmination of an uncontrolled inflammatory response to some initial event, mediated by an as yet incompletely understood interplay of cytokines, complement, and the coagulation system. In the setting of acutely ill non-transplant patients, this has been termed the systemic inflammatory response syndrome. 1 This syndrome has been well described in patients with trauma or severe infection, [1] [2] [3] but has only recently been recognized in patients undergoing HSCT.
The occurrence of single organ system dysfunction in the post-transplant period has been shown to predict for subsequent development of multiple organ dysfunction and death. McDonald and coworkers 4 showed that development of hepatic dysfunction, manifesting as veno-occlusive disease, predicted for subsequent multiorgan failure and death. We have previously shown that development of pulmonary dysfunction predicted for and preceded multiorgan failure in another group of patients undergoing HSCT. 5 Although the first organ involved differed in these two reports, the combined data support the contention that single organ dysfunction is not a disorder confined to one organ, but a manifestation of a more generalized abnormality.
The latter study also assessed the development of CNS dysfunction, defined as lethargy or confusion, and showed a significant correlation between CNS dysfunction and subsequent second organ dysfunction and death. As part of a larger study of organ dysfunction following HSCT, we identified a group of patients who developed evidence of mental status changes in the absence of any other detectable organ dysfunction. Herein, we describe the characteristics of this isolated CNS dysfunction, and its relationship to multiple organ dysfunction syndrome (MODS) after HSCT.
Methods

Patients
This analysis was based on 186 adult patients (mean age 44.0 years, range 19-70) undergoing autologous or allogeneic HSCT at the University of Nebraska Medical Center over an 18-month period between December 1995 and May 1997. Patient characteristics are shown in Table 1 . Various preparative regimens were used, based on diagnosis. However, 180 of 186 patients (97%) were prepared with one of (9) six different regimens ( Table 2 ). The preparative regimen included total body irradiation in 58 cases (31%).
For the purpose of the analysis of medication intake, patients who developed CNS dysfunction as their first organ dysfunction were matched to control patients without organ dysfunction, based on HSCT type, diagnosis, and days post-HSCT. Total daily dose and total daily dose per body weight were recorded for CNS active medications (morphine, meperidine, diphenhydramine, lorazepam) on the day prior to, and the day of development of CNS dysfunction.
Transplant practices
Because adverse events occurring after HSCT were postulated to be related to the toxicity of the preparative regimens, the first day of the preparative regimen is considered day 1 in this report.
Adverse events
Patients were monitored daily, beginning on the first day of the preparative regimen, for the following adverse clinical events: (1) Central nervous system (CNS) dysfunction: defined by decrease in Folstein mini-mental status exam 6 by greater than four points from the baseline. Since interobserver variability was ±2 points, this range approached 2 standard deviations. (2) Pulmonary dysfunction: defined by the presence of hypoxia (oxygen saturation of less than 90% using finger oximetry) on two occasions separated by 
Statistics
All data are expressed as means ± standard error. Analysis of variance (ANOVA) and t-tests were used to compare continuous variables. Fisher's exact test was used to compare categorical variables. A P value of р0.05 was considered significant.
Results
Incidence and predisposing factors for CNS dysfunction
Of the 186 patients studied, 21 (11%) developed CNS dysfunction as their first organ dysfunction, and 28 developed a different organ dysfunction (either pulmonary or hepatic) as their first organ dysfunction. Time to development of first organ dysfunction was no different between these two groups (mean 22.8 ± 0.9 days after start of the preparative regimen for CNS dysfunction vs 21.1 ± 1.1 days for other dysfunctions). One hundred and thirty-seven patients developed no organ dysfunction ( Figure 1 ).
Comparing the 21 patients who developed CNS dysfunction as their first organ dysfunction with the 137 patients who developed no organ dysfunction, patients developing CNS dysfunction as the first dysfunction were more likely to have undergone allogeneic HSCT (P = 0.001) and to have been prepared with a TBI-based preparative regimen (P = 0.001), and were less likely to be undergoing HSCT for lymphoma (P = 0.008). Development of CNS dysfunction as a first dysfunction did not correlate with age or with the source of stem cells (bone marrow vs peripheral blood). In a multivariate analysis utilizing the same factors, allogeneic stem cell source was the only statistically significant predictor of CNS dysfunction. Patients undergoing allogeic HSCT were more likely to develop CNS dysfunction (P value = 0.0013, odds ratio = 4.83 with confidence interval of 1.86 to 12.50).
Patients who developed CNS dysfunction as their first organ dysfunction were matched to control patients without organ dysfunction, based on HSCT type, diagnosis, and days post-HSCT. There were no consistent or clinically relevant differences in doses (total daily dose and total daily dose per kilogram body weight) of CNS active medications (morphine, meperidine, diphenhydramine, lorazepam) given to patients who developed CNS dysfunction vs patients who did not develop CNS dysfunction (Table 3) . For example, on the day prior to development of CNS dysfunction, patients who would subsequently develop CNS dysfunction received marginally more diphenhydramine (50 ± 35 mg vs 20 ± 7 mg, P = 0.08) but less lorazepam (1 ± 0.4 mg vs 2 ± 1.5 mg, P = 0.03). There were no statistically significant differences in medication intake occurring on the day of development of CNS dysfunction. A larger proportion of patients who would subsequently develop CNS dysfunction received lorazepam on the day prior to dysfunction (13/21 vs 6/21, P = 0.06) or on the day of development of organ dysfunction (11/21 vs 4/21, P = 0.05) ( Table 3 ). However, since the patients with dysfunction received less total dose on that day than did patients without dysfunction, the relevance of this is unclear. There were no statistically significant differences in the proportion of patients receiving morphine or diphenhydramine.
Outcome of patients with CNS dysfunction
Although the transplant-related mortality was low overall in this patient population, patients who developed CNS dysfunction were more likely to die before day 28 than were those with no organ dysfunction (P Ͻ 0.02). Furthermore, patients who developed CNS dysfunction as their first dysfunction had a similar mortality to patients who developed a different dysfunction (P = 0.68).
Patients with CNS dysfunction who did not develop second organ dysfunction were significantly more likely to survive to day 100 than were those who did develop second organ dysfunction. Of the 21 patients who developed CNS Table 3 Relationship between use of CNS active medications and development of CNS dysfunction Bone Marrow Transplantation dysfunction 10 patients (48%) resolved their dysfunction a mean of 4.6 ± 5.8 days (range 1-21) later without progression to second dysfunction. 90% of these patients survived to day 100. Of the 21 patients who developed CNS dysfunction, 11 (52%) progressed to second organ dysfunction (either pulmonary or hepatic) a mean of 5.5 ± 5.7 days after the CNS dysfunction (range 0-19). Only 36% survived to day 100 (P = 0.02). While patients receiving allogeneic stem cell transplants or who were prepared with TBI-based regimens were at a higher risk of developing CNS dysfunction, there were no readily identifiable factors which predicted for progression to MODS and death. Progression to second organ dysfunction was not correlated with type of HSCT (allogeneic vs autologous), stem cell source (bone marrow vs peripheral blood), age, diagnosis or use of a TBI-containing preparative regimen.
Discussion
Changes in mental status (defined as changes in the Folstein mini-mental status examination) are a relatively frequent occurrence after high-dose therapy and stem cell rescue. In our series, these changes occurred as the first organ dysfunction in 11% of patients. Nonetheless, occurrence of this dysfunction carried an increased risk of transplant-related mortality. More than 50% progressed to second organ dysfunction (either pulmonary or hepatic), and only 36% survived to day 100.
Neurologic complications of high-dose therapy and stem cell transplantation have been reported previously.
9-14 Our report differs in several important ways from these previous series. Encephalopathy has been a frequent finding in earlier reports, occurring in 30-40% of patients. However, these studies have defined neither the mechanism for detection of an altered mental status nor the threshold for considering the altered mental status abnormal. It is also unclear from these studies if patients were examined for alterations in mental status prospectively and in a uniform manner, raising the possibility of under-diagnosing the disorder. Our study used a tool for detection of alterations in mental status that is standardized and whose validity and limitations have been established. 15 The definition of the degree of alteration of mental status that was considered abnormal was also precisely and prospectively defined in our patient population. The tool for detection of encephalopathy was applied prospectively on a daily basis, minimizing the likelihood that patients with mild alterations would be missed. This mechanism of defining and detecting alterations in mental status minimizes the likelihood of underdiagnosis and provides a basis for duplication in other transplant centers.
Previous descriptions of neurologic complications of marrow transplantation have taken into consideration all neurologic complications seen in all patients, including those with concurrent liver, renal and/or lung disease. In many of these patients a diagnosis of metabolic encephalopathy due to these organ dysfunctions was made.
Unfortunately, a precise link between the liver, lung or kidney dysfunction and the altered mental status is difficult to establish with certainty in an individual patient. The prognosis of these individuals obviously includes the outcome of their underlying organ dysfunctions, as well as their neurologic status. Our study describes the outcome of patients whose CNS dysfunction was their first detected organ dysfunction. These patients were free of evidence of significant renal, hepatic or pulmonary dysfunction at the time the altered mental status was detected. Consequently, the patients described in our study provide a more accurate depiction of the clinical outcome of patients with isolated CNS dysfunction in whom no other coexistent organ dysfunction can be found to contribute to an adverse clinical outcome.
Finally, no previous analysis of CNS dysfunction during transplantation has considered the effect of CNS-active medication. Clinically, isolated alterations in mental status in patients without other organ dysfunction are often ascribed to medication effects. Our analysis suggests this is unlikely for two reasons. The first is the analysis of the use of CNS depressants during and prior to the development of CNS dysfunction. On the day prior to the detection of CNS dysfunction, the patients destined to develop this complication used a mean of 1 mg less lorazepam, but 30 mg more diphenhydramine. On the day that CNS dysfunction was detected, there was no difference in the doses of these medications used by patients with and without this complication. The second is the high likelihood of death conferred by the detection of CNS dysfunction. It is unlikely that the alteration of mental status induced by these medications can account for a 64% mortality over the subsequent 3 months, a mortality rate significantly higher than that of patients without detectable CNS dysfunction.
Rather than a medication effect, we postulate that isolated CNS dysfunction occurring in patients after high-dose therapy and HSCT represents the initial manifestation of a systemic disorder (MODS), which is a risk factor for subsequent morbidity and mortality. Isolated CNS dysfunction has similar systemic correlates to other isolated organ dysfunctions. We have previously shown that development of CNS dysfunction is associated with decreases in circulating anticoagulants protein C and antithrombin, in a manner identical to that seen in patients with pulmonary dysfunction 5 and hepatic VOD. 5, 16 CNS dysfunction is also associated with increased platelet transfusion requirement, as are pulmonary and renal dysfunctions, 17 and hepatic VOD. 4, 17, 18 Furthermore, in this and other series addressing organ dysfunction in general, 5 isolated CNS dysfunction has outcomes identical to those seen in patients' pulmonary or hepatic dysfunctions: an increased risk of subsequent development of other organ dysfunctions, and death. In the series focusing on neurologic complications of transplantation, encephalopathies are most often said to occur along with pulmonary, renal or hepatic dysfunction. [10] [11] [12] [13] Further, development of 'CNS complications' was often followed by multiorgan failure and death. Antonini and coworkers 12 found a significant decrease in probability of survival at day 90 among patients with 'significant CNS complications'. Because CNS, pulmonary and hepatic dysfunctions during transplantation all have the same correlates (lower levels of antithrombin III and protein C, and a higher number of platelet transfusions) and the same outcomes (higher incidence of subsequent development of the other organ dysfunctions and death) and generally have no alternative explanation we postulate that these organ dysfunctions are individual components of a larger disorder, similar to that seen in other populations of critically ill patients where it is termed the multiple organ dysfunction syndrome (MODS). 19, 20 This syndrome of gradual and sequential failure of virtually all organ systems is felt to be a systemic disorder, not confined to a one organ system, that is the end result of an incompletely understood interplay between numerous cytokines, the complement cascade, the hemostatic system, the kinin-generating pathways, vascular endothelial cells and other unrecognized elements induced by a wide spectrum of noxious stimuli from infections to thermal burns. In marrow and blood transplantation, the preparative regimen is felt to be the initial stimulus to the development of this syndrome, 21 with the possibility of non-bacteremic infections and other phenomena (such as platelet transfusion) adding to the intensity of the original stimulus. As a component of this systemic and highly lethal syndrome, the subsequent development of other complications and high mortality of isolated CNS dysfunction can be readily understood.
The implications of this data to the clinical practice of blood and marrow transplantation are potentially significant. The Folstein MMSE is an easy instrument to use with minimal training, has good intra-and interobserver reproducibility, 6, 15 does not require unusual technology to perform, and is not expensive to use. It is a good tool to use for the purpose of early identification of patients at risk for other complications and death. At the very least, patients developing CNS dysfunction are not candidates for cessation of close, active clinical monitoring and intense supportive care. At most, these patients may then be candidates for interventions designed to alter the progression of single organ dysfunction to MODS, such as use of antithrombin III concentrate. [22] [23] [24] [25] Such studies need to be conducted, as well as studies designed to detect patients at risk for development of CNS dysfunction and MODS prior to its actual recognition clinically.
